Handbook of Clinical medicine

found, there’s no way to tell for sure if it will impinge on health. You might end up having a bad eff ect from treatment that wasn’t needed. • There is much uncertainty on treating those who do turn out to have prostate cancer: options are radical surgery to remove the prostate (risks erectile dys- function and incontinence), radiotherapy, or hormones. • Screening via PSA has shown confl icting results. Some RCTS have shown no dif- ference in the rate of death from prostate cancer, others have found reduced mortality, eg 1 death prevented per 1055 men invited for screening (if 37 cancers detected). Ultimately, you must decide for yourself what you want. Prognostic factors in prostate cancer A number of prognostic factors help determine if ‘watchful waiting’ or agg ressive therapy should be advised: •Pre-treatment PSA level. •Tumour stage (as measured by the TNM system; p523). •Tumour grade—Gleason score. Gleason grading is from 1 to 5, with 5 being the highest grade, and carrying the poorest prognosis. Gleason grades are decided by analysing histology from two separate areas of tumour specimen, and adding them to get the total Gleason score for the tumour, from 2 to 10. Scores 8–10
